This center treats primary substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
Recovery.com has connected directly with this treatment provider to validate the information in their profile.
This center treats primary substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
Hickory Treatment Centers accepts most major insurance plans. Call to verify coverage and discuss payment options.
This addiction treatment center in Rockville, Indiana offers accessible and effective care through comprehensive treatment services including detox for alcohol and drug addiction, with medication-assisted treatment (MAT) if needed. Depending on the level of care that each client needs, they can either attend a residential program or Hickory Recovery’s intensive outpatient program (IOP). On average, most clients go to residential treatment for 28 days and outpatient treatment for 30-60 days. Clients attend IOP for 3 days a week on Mondays, Wednesdays, and Fridays 3 hours daily. Additionally, transportation to and from treatment can be arranged.
Each client can rest assured that their unique needs will be addressed because each treatment plan is customized. The clinicians use a combination of evidence-based therapies and holistic approaches to treat addiction. They will commonly use cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), yoga, nutritional counseling and recreational therapy.
The staff at Hickory knows that mental health is often impacted alongside an addiction. Their clinicians are trained to treat both the addiction and the co-occurring disorder at the same time, as they are directly linked to each other. Some of the most common co-occurring disorders they treat are depression, anxiety, bipolar and post-traumatic stress disorder (PTSD).
These highlights are provided by and paid for by the center.
Joint Commission Accredited
This center primarily treats substance use disorders, helping you stabilize, create relapse-prevention plans, and connect to compassionate support.
The Joint Commission accreditation is a voluntary, objective process that evaluates and accredits healthcare organizations (like treatment centers) based on performance standards designed to improve quality and safety for patients. To be accredited means the treatment center has been found to meet the Commission's standards for quality and safety in patient care.
Medication-Assisted Treatment (MAT) is an evidence-based approach that pairs FDA-approved medications with counseling to treat addiction. The medications are used to reduce cravings, ease withdrawal symptoms, or block the effects of substances. More about MAT
Dolophine®, Methadose®
Methadone is a full opioid agonist, meaning it activates opioid receptors in the brain to produce effects like pain relief and euphoria. It is longer acting than many other opioids, making it useful in medication-assisted treatment for opioid use disorder.
It reduces withdrawal symptoms and cravings by occupying opioid receptors without causing intense highs. Because it is a full agonist, it must be used carefully to avoid overdose, but it is highly effective when taken as prescribed within a structured program.
Vivitrol®, Revia®
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and prevents opioids from producing effects like euphoria or sedation. It is used to treat both opioid and alcohol use disorders, but does not cause physical dependence or withdrawal.
It helps reduce cravings and the rewarding effects of opioids or alcohol, supporting long-term recovery. Because it blocks opioid effects, it should only be started after a person has fully detoxed from opioids to avoid triggering withdrawal.
Suboxone®, Subutex®, Sublocade®, Zubsolv®
Buprenorphine is a partial opioid agonist used to treat opioid use disorder. It activates opioid receptors to reduce cravings and withdrawal but has a ceiling effect, meaning it produces less euphoria and respiratory depression than full opioids.
Buprenorphine binds tightly to opioid receptors, blocking other opioids from attaching and reducing the risk of misuse. It's often combined with naloxone (as in Suboxone®) to discourage injection misuse and is available in daily or monthly forms.